Marstacimab in Patients with Hemophilia A or B
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.
Barbara Burton, MD, Northwestern University, discusses enzyme replacement therapy in patients with mucopolysaccharidosis (MPS) IVA.
PFA Opens May 7, 2024 Applicant Town Hall May 14, 2024; 12 pm (ET) Letter of Intent (LOI) Deadline June 4, 2024; 5 pm (ET)…
Submission deadline – June 12, 2024 NORD notifies authors of acceptance – July 23,
/PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases,…
Website Disclaimer The information provided in the Dysautonomia Foundation web site is intended to educate the reader about certain medical conditions and certain possible treatments.…
“Every 90 Minutes” has been a tagline that organizations have used for over a decade to describe how often someone dies from ALS in the…
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis
There is a lot that the Bears Hall of Famer can’t do anymore, but he can still connect with the people who have been important…
Gland Pharma Ltd. announced on Tuesday that the US health government has approved its generic Edaravone injection for the treatment of amyotrophic lateral sclerosis.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this